Every material Form 8-K Novanta filed with the SEC in 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Novanta reported third quarter 2026 results on November 9, 2026. GAAP revenue rose 23% to $305 million, while GAAP net income fell to $2 million from $10.7 million and GAAP diluted EPS fell to $0.05 from $0.30. The company also updated its full-year 2026 outlook, now expecting GAAP revenue of $1,135 million to $1,140 million, and said it closed its largest acquisition in company history, Riverpoint Medical.
Q3 2026 GAAP revenue was $305 million, up 23.1% from $247.8 million; Adjusted EBITDA rose 38.3% to $80.3 million.
GAAP operating income was $13.9 million versus $21.8 million a year earlier, and restructuring, acquisition, and related costs were $23.1 million.
Adjusted diluted EPS was $1.05, up 20.7% from $0.87; operating cash flow was $39.3 million versus $8.5 million.
For full-year 2026, the company now expects GAAP revenue of $1,135 million to $1,140 million and Adjusted EBITDA of $274 million to $277 million.
Novanta reported second quarter 2026 results for the period ended July 3, 2026, with GAAP revenue up 10% to $266 million and GAAP net income of $12.5 million, compared with $4.5 million a year earlier. The company also updated its third quarter and full year 2026 guidance to include the recently closed Riverpoint Medical acquisition, which it says roughly doubles its recurring medical consumables business.
GAAP diluted EPS was $0.30 versus $0.12 a year earlier; Adjusted Diluted EPS rose 17.1% to $0.89.
Adjusted EBITDA rose 16.4% to $60.7 million, with an Adjusted EBITDA margin of 22.8%.
Q3 2026 guidance: GAAP revenue of $300 million to $304 million and Adjusted Diluted EPS of $0.95 to $1.00.
Full year 2026 guidance: GAAP revenue of $1,130 million to $1,140 million and Adjusted Diluted EPS of $3.68 to $3.74.
Novanta completed its acquisition of Riverpoint Medical on July 23, 2026, paying the seller approximately $1.2 billion in cash, subject to customary adjustments, with a further $250.0 million milestone payment due by January 8, 2027. The company funded the deal by borrowing $616.0 million under its credit facilities and using cash on hand, bringing consolidated debt to $854.7 million as of July 22, 2026. The company expects the deal to add $0.18 to $0.25 of adjusted earnings per share in 2027, its first full year after closing.
Closed July 23, 2026, with approximately $1.2 billion paid in cash at closing
$250.0 million milestone payment remains payable to the seller on or before January 8, 2027
$616.0 million borrowed under revolving and delayed draw term loan facilities; consolidated debt $854.7 million as of July 22, 2026
Expected to contribute $0.18 to $0.25 of adjusted EPS in 2027; 2026 impact to be discussed on the second quarter earnings call
Novanta agreed on June 8, 2026 to sell 2,142,857 common shares at $140.00 each in a private placement to institutional and accredited investors, for an aggregate purchase price of approximately $300.0 million before placement agent fees and expenses. The closing is expected on June 11, 2026, subject to customary conditions, and the company agreed to register the resale of the shares, which would add to the share count for existing holders.
Purchase price: $140.00 per share, 2,142,857 shares, about $300.0 million aggregate
Expected closing on or about June 11, 2026, subject to customary closing conditions
Post-closing count: 42,473,345 common shares outstanding or issuable under Tangible Equity Units, based on 35,613,303 shares outstanding as of June 8, 2026
Registration statement due within 30 days after closing; placement agents include J.P. Morgan Securities LLC and PNC Capital Markets LLC
Novanta agreed on June 8, 2026 to acquire Riverpoint Medical from Arlington Capital Partners for $1.2 billion in cash at closing, plus a $250 million milestone payment due by January 8, 2027. The deal is funded with cash on hand, existing credit facilities and a $300 million equity raise, and the credit agreement was amended to raise the permitted leverage ratio, which means more debt for shareholders to carry. The company expects the deal to close in the third quarter of 2026 and says it will update guidance after closing.
Purchase price of $1.2 billion in cash at closing, subject to customary adjustments, plus a $250 million milestone payment due on or before January 8, 2027
Financing from cash on hand, existing credit facilities and a recently completed $300 million equity raise
Credit agreement amended: permitted consolidated leverage ratio raised to 4.00 to 1.00, or 4.50 to 1.00 for four quarters after a designated acquisition
Expected net leverage of about 2.7x at closing in the third quarter of 2026, with a target below 2.3x by year-end 2027; standalone 2026 guidance was confirmed
Novanta entered into a Second Amendment to its Fourth Amended and Restated Credit Agreement with Bank of America, N.A. as administrative agent. The amendment establishes $200.0 million of delayed draw term loan commitments that the company can borrow against for up to six months, with maturity on June 27, 2030. The filing gives no use of proceeds, so the effect on shareholders depends on whether and how the company draws the loans.
Second Amendment dated May 15, 2026 amends the credit agreement originally dated June 27, 2025
$200.0 million of delayed draw term loan commitments, available for up to six months after May 15, 2026
Loans mature June 27, 2030; interest is tied to the company's consolidated leverage ratio, with a commitment fee on undrawn amounts
Amortization begins on or around the last business day of the fiscal quarter ending September 25, 2026
Novanta reported first-quarter 2026 results for the period ended April 3, 2026. GAAP revenue rose 10.4% to $257.7 million, but GAAP net income was $21.1 million versus $21.2 million a year earlier, and GAAP diluted EPS fell to $0.51 from $0.59, while Adjusted Diluted EPS rose 9.5% to $0.81. The company issued new guidance for the second quarter and full year 2026.
GAAP revenue increased 10.4% to $257.7 million; organic revenue growth was 3.1%.
GAAP operating income was $27.5 million versus $32.4 million a year earlier.
Second-quarter 2026 guidance: GAAP revenue of $259 million to $264 million and Adjusted Diluted EPS of $0.81 to $0.86.
Full-year 2026 guidance: GAAP revenue of $1,040 million to $1,055 million and Adjusted Diluted EPS of $3.50 to $3.65.
Novanta reported fourth-quarter and full-year 2025 results on February 23, 2026, with quarterly GAAP revenue up 9% and adjusted diluted EPS up 20%. Full-year GAAP diluted EPS fell to $1.47 from $1.77, and operating cash flow declined sharply, while the company issued 2026 revenue guidance of $1,030 million to $1,050 million.
Q4 2025 GAAP revenue was $258.3 million, up 9%, while GAAP diluted EPS was $0.45 versus $0.46 a year earlier.
Q4 2025 adjusted diluted EPS was $0.91, up 20%; operating cash flow was $8.8 million versus $61.6 million.
Full-year 2025 GAAP revenue was $980.6 million, up 3.3%, and GAAP diluted EPS was $1.47 versus $1.77.
2026 guidance: GAAP revenue of $1,030 million to $1,050 million and adjusted diluted EPS of $3.50 to $3.65.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Novanta filing is on SEC EDGAR ↗. 8-K briefs of other companies →